Mayo Clinic Talks

Hosted ByMayo Clinic

Timely consultations relevant for family medicine, primary care, and general internal medicine topics for physicians, nurse practitioners, physician assistants, and residents. Offering CME credit for most episodes

Mayo Clinic Talks 255: Regenerative Medicine Edition Ep.10: FDA Regulatory Process and Clinical Trials

To claim credit for this episode, visit: http://www.ce.mayo.edu/regmedonline

Guest: Drew M. Witter, CCRP

Host: Darryl S. Chutka, M.D. (@ChutkaMD)

“Stem Cell Clinics” throughout the U.S. promote stem cell therapy for a variety of health conditions including osteoarthritis, autism, macular degeneration, Parkinson’s Disease, Alzheimer’s Disease and most recently COVID-19 infections. How can our patients be assured that the regenerative medicine therapy effectively treats their health condition and the products they receive are safe? In this podcast, we discuss regulations regarding regenerative medicine, the process of obtaining FDA-approval and which regenerative medicine therapies are FDA-approved. Our guest will be Drew Witter, a Program Manager from the Office of Research and Regulatory Support at the Mayo Clinic.

Specific topics discussed:

  • Process of taking regenerative medicine from the research lab to the clinical practice
  • How regulators ensure the safety and effectiveness of regenerative therapies
  • The process of acquiring FDA-approval
  • Regenerative medicine therapies that are FDA-approved
  • How patients and clinicians learn of FDA-regulated regenerative medicine clinical trials

Additional resources:

Additional educational opportunities from Mayo Clinic:

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Este sitio usa Akismet para reducir el spam. Aprende cómo se procesan los datos de tus comentarios.